[Treatments for rare ovarian tumors: What's new?]

Area of Science:

• Gynecologic Oncology
• Clinical Trial Design
• Rare Diseases

Context:

• Rare ovarian tumors (ROT) collectively account for nearly half of all ovarian neoplasms, despite individual low incidence.
• Effective management necessitates dedicated clinical trials due to the collective burden of these rare entities.
• Increasing institutional networks and collaborations have facilitated a rise in ROT-focused clinical trials.

Purpose:

• To summarize the evolution and current landscape of clinical trials for rare ovarian tumors (ROT).
• To highlight the shift towards molecular-driven and master protocol trials for personalized medicine in ROT.
• To underscore the importance of clinical trials in improving the treatment and outcomes for patients with rare ovarian tumors.

Summary:

• The collective incidence of rare ovarian tumors (ROT) necessitates specialized clinical trials for improved management.
• Clinical trial designs for ROT have diversified, focusing on molecular features, novel agents, and randomized comparisons.
• Emerging molecular-driven trials, including master protocols, hold promise for advancing personalized medicine in ROT.

Impact:

• Clinical trials are essential for advancing the understanding and treatment of rare ovarian tumors.
• The development of innovative trial designs, such as master protocols, is key to personalized medicine for ROT.
• Increased collaborative efforts and dedicated trials are improving therapeutic strategies and patient outcomes for rare ovarian neoplasms.